Vaccin contre le zona: quelles recommandations en 2014?

Details

Serval ID
serval:BIB_BE7F2BCA799D
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Vaccin contre le zona: quelles recommandations en 2014?
Journal
Revue médicale suisse
Author(s)
Vionnet Julien, Hart Karen, Spertini François
Publication state
Published
Issued date
16/04/2014
Language
french
Abstract
Zostavax, a live attenuated vaccine against shingles (herpes zoster) has been available in Switzerland since 2008. In a population aged 60 and over, evidence suggests the vaccine effectively reduces the incidence of shingles and some of its corresponding complications. More importantly, in terms of public health, vaccination appears to reduce the burden of illness and be pharmaco-economically viable. Despite being part of the vaccination programmes in the United States and several European countries, the vaccine is not yet part of the Swiss vaccination programme. Should Switzerland follow suit by incorporating Zostavax into their vaccination policy?
Create date
16/11/2021 14:34
Last modification date
28/12/2021 6:36
Usage data